Omalizumab back in favour in draft NICE guidance
14:48 EST 8 Mar 2013 | Pharmaceutical Journal
The National Institute for Health and Clinical Excellence has performed another U-turn regarding its advice on omalizumab (Xolair) for the treatment of asthma. In final draft guidance, published this week (7 March 2013), NICE recommends omalizumab..
Original Article: Omalizumab back in favour in draft NICE guidance
More From BioPortfolio on "Omalizumab back in favour in draft NICE guidance"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
